Renaissance Technologies LLC Increases Stock Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)

Renaissance Technologies LLC raised its position in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 146.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 618,942 shares of the company's stock after acquiring an additional 368,071 shares during the quarter. Renaissance Technologies LLC owned approximately 0.23% of Autolus Therapeutics worth $1,455,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Street Corp lifted its position in shares of Autolus Therapeutics by 1.7% during the 3rd quarter. State Street Corp now owns 606,544 shares of the company's stock worth $2,202,000 after purchasing an additional 10,401 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Autolus Therapeutics by 145.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company's stock worth $4,663,000 after buying an additional 761,008 shares during the last quarter. Hennion & Walsh Asset Management Inc. acquired a new position in shares of Autolus Therapeutics during the 4th quarter worth about $611,000. Avanza Fonder AB acquired a new position in shares of Autolus Therapeutics during the 4th quarter worth about $75,000. Finally, Arkadios Wealth Advisors purchased a new position in shares of Autolus Therapeutics in the 4th quarter valued at about $47,000. Institutional investors and hedge funds own 72.83% of the company's stock.

Analysts Set New Price Targets

AUTL has been the subject of several recent analyst reports. Truist Financial decreased their target price on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Wells Fargo & Company reduced their price objective on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a research report on Friday, March 21st. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research report on Thursday, April 10th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $9.32.

Autolus Therapeutics Stock Down 4.3 %

NASDAQ:AUTL traded down $0.06 during mid-day trading on Thursday, reaching $1.35. 1,355,422 shares of the stock were exchanged, compared to its average volume of 1,447,912. The stock has a market capitalization of $359.23 million, a P/E ratio of -1.12 and a beta of 2.06. Autolus Therapeutics plc has a 1 year low of $1.11 and a 1 year high of $5.00. The company has a 50 day simple moving average of $1.60 and a 200-day simple moving average of $2.41.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its earnings results on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.12. The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $2.98 million. As a group, research analysts predict that Autolus Therapeutics plc will post -0.94 EPS for the current year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.